Jeffrey Bradley, MD, Radiation Oncology, Atlanta, GA, Emory University Hospital Midtown

JeffreyDBradleyMDFASTRO

Radiation Oncology Atlanta, GA

Thoracic Cancer

Professor of Radiation Oncology Emory University School of Medicine

Dr. Bradley is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Bradley's full profile

Already have an account?

Education & Training

  • University of Chicago
    University of ChicagoResidency, Radiation Oncology, 1994 - 1998
  • Evanston HospitalInternship, Internal Medicine, 1993 - 1994
  • University of Arkansas for Medical Sciences College of Medicine
    University of Arkansas for Medical Sciences College of MedicineClass of 1993

Certifications & Licensure

  • GA State Medical License
    GA State Medical License 2019 - 2021
  • MO State Medical License
    MO State Medical License 1998 - 2022
  • IL State Medical License
    IL State Medical License 1993 - 2020
  • American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2010-2014
  • America's Top Doctors for Cancer Castle Connolly, 2009-2013
  • CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • PACIFIC-2: Phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage III NSCLC. 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

  • Jeffrey Bradley, MD, on RTOG 0617 Results in Advanced Lung Cancer
    Jeffrey Bradley, MD, on RTOG 0617 Results in Advanced Lung CancerFebruary 21st, 2020
  • Standard of Care Chemoradiation for Stage III NSCLC Is Superior to Two Tested Alternatives
    Standard of Care Chemoradiation for Stage III NSCLC Is Superior to Two Tested AlternativesDecember 16th, 2019
  • Long-Term Survival Rates More Than Double Previous Estimates for Locally Advanced Lung Cancer
    Long-Term Survival Rates More Than Double Previous Estimates for Locally Advanced Lung CancerNovember 10th, 2017
  • Join now to see all

Committees

  • Member, Definitive and Adjuvant Radiotherapy in Locally Advanced Non-small Cell Lung Cancer Guideline Panel, American Society for Radiation Oncology 2015 - Present

Professional Memberships

Hospital Affiliations